About Zoliget 15/2mg Tablet
Zoliget 15/2mg Tablet is an effective treatment of diabetes type 2. This medication is a combination of two drugs. Diabetes type 2 is normally seen in older people and causes severe issues of the body and brain. Zoliget 15/2mg Tablet is used to maintain the blood sugar level normal. This primes to the reduction of diabetes-caused issues.
How effective is Zoliget 15/2mg?
Zoliget 15/2mg Tablet belongs to the group of anti-diabetic medicines. It is oral hypoglycemia. Zoliget 15/2mg Tablet contains two drugs, Pioglitazone 15mg and Glimepiride 2mg. Glimepiride works by increasing the amount of insulin in the body. It belongs to the sulfonylurea group of medicines. Pioglitazone belongs to the group of medicines known as Thiazolidinediones. Both of these medicines help the body against diabetes type 2.
Can I buy Zoliget 15/2mg online in Pakistan?
Yes! You can buy Zoliget 15/2mg Tablets online through our website or call us at 0311 113 6337.
What dose should I choose?
For adults (18 and above), take 1 Zoliget 15/2mg 1 to 2 tablets a day.
Zoliget 15/2mg is not suggested for use in children (17 or younger).
If you have any queries about Zoliget 15/2mg, please contact your doctor or a pharmacist.
What are the side effects and other warnings when taking Zoliget 15/2mg?
Every product with an active ingredient has side effects, however they rare.
Some common side effects of Zoliget 15/2mg:
- Oedema
- Hypoglycemia
- Headache
- Heart failure
- Sinus infection
- Sore throat
Zoliget 15/2mg Tablet’s warnings include;
- Share your medical history, especially of clotting problems, blood disorders, heart disease, swelling, stroke, high blood pressure, and asthma with your doctor before using Zoliget 15/2mg.
- Consult your doctor before using Zoliget 15/2mg tablet if you are pregnant or breastfeeding.
- Do not use Zoliget 15/2mg tablet if you have bladder cancer.
- Zoliget 15/2mg can cause liver issues, so do not use it without doctor’s consent if you already have liver problems.
Reviews
There are no reviews yet.